Andy, I've been hoping for that. Perhaps, at the upcoming conference. Beating Tamoxifen by 100%, in ugly, naked mice, if hyped correctly, could do wonders.
I have made about 6 bad predictions in a row, but....... I think that LGND's stock might jump up quite a bit on the NDA filing for Panretin Topical.
It's the first topical ointment treatment for cancer! Even though they are only getting approval for KS, to me, it has much greater possibilities. Plus, if it is hyped correctly, the public might react.
But, would a doctor use Panretin, off label, for the treatment of skin cancel? I don't know. It could be used, perhaps, as additional protection. First, remove the cancer thru surgery, and then treat with Panretin as additional insurance!?
Good luck, Bob |
